血清胸苷激酶1在恶性肿瘤诊断和疗效评估中的意义  

Significance of detecting serum thymidine kinase 1 in diagnosis and efficacy evaluation for malignant tumors

作　　者：周菊英[1] 姚怡敏[1] 俞志英[1] 徐晓婷[1] 秦颂兵[1] 吴琼[1] 赵奇[1] 许愿[1] 

机构地区：[1]苏州大学附属第一医院放疗科,江苏省215006

出　　处：《江苏医药》2012年第9期1055-1058,共4页Jiangsu Medical Journal

摘　　要：目的探讨血清胸苷激酶1(STK1)水平变化在恶性肿瘤诊断和疗效评估中的意义。方法收集不同病理类型、病种、临床分期恶性肿瘤患者103例放疗前、中、后的血清样本,采用印迹免疫-增强化学发光法检测STK1水平。取49例健康体检者血清标本作为对照。结果恶性肿瘤患者放疗前STK1水平为(2.21±0.85)pmol/L,显著高于放疗后的(1.59±0.48)pmol/L和对照组的(1.36±0.86)pmol/L(P<0.05)。放疗前STK1阳性率为56.41%,显著高于放疗后的16.90%和对照组的10.20%(P<0.05)。放疗前头颈部恶性肿瘤患者STK1水平为(1.99±0.64)pmol/L,显著低于胸腹部恶性肿瘤的(2.51±1.1)pmol/L(P<0.05)。放疗后部分缓解患者STK1水平为(1.67±0.47)pmol/L,显著高于完全缓解患者的(1.40±0.48)pmol/L(P<0.05)。放疗后,急性皮肤黏膜反应为Ⅱ度及以上组的STK1水平为(1.76±0.37)pmol/L显著高于I度及以下组的(1.50±0.52)pmol/L(P<0.05)。结论 STK1是恶性肿瘤辅助检查的可靠指标,对恶性肿瘤患者的筛检、诊断、治疗效果评估等有重要的参考价值。Objective To evaluate the significance of detecting serum thymidine kinase 1（STK1） in the diagnosis and efficacy evaluation for malignant tumors. Methods The samples were collected from 103 cases with different kinds of malignant tumors in the different periods of radiotherapy.Serum STK1 was measured by sensitive chemiluminescence dot-blot assay.The results were compared to those in healthy controls（group C）. Results Serum STK1 in patients with malignant tumors before radiotherapy was （2.21±0.85） pmol/L,which was higher than（1.59±0.48） pmol/L after radiotherapy and（1.36±0.86） pmol/L） in group C（P0.05）.The positive rate of STK1 in patients with malignant tumors before radiotherapy was 56.41%,which was higher than 16.90% after radiotherapy and 10.20% in group C（P0.05）.Serum STK1 before radiotherapy in the patients with cephalocervical malignant tumors was（1.99±0.64） pmol/L,which was lower than （2.51±1.10） pmol/L in the patients with abdominal malignant tumors（P0.05）.Serum STK1 before radiotherapy in the patients with partial remissive malignant tumors was （1.67±0.47） pmol/L, which was higher than（1.54±0.47） pmol/L in complete remissive patients（P0.05）.After radiotherapy,serum STK1 in the patients with severe skin and mucosa reaction was（1.76±0.37） pmol/L,which was higher than（1.50±0.52） pmol/L in the patients with mild skin and mucosa reaction（P0.05）. Conclusion Serum STK1 is a reliable marker for screening and evaluating therapeutic efficacy and prognosis in the patients with malignant tumors.

关 键 词：胸苷激酶1 恶性肿瘤 

分 类 号：R730[医药卫生—肿瘤]